Literature DB >> 29705093

No firm evidence that lack of blinding affects estimates of mortality in randomized clinical trials of intensive care interventions: a systematic review and meta-analysis.

Carl Thomas Anthon1, Anders Granholm2, Anders Perner3, Jon Henrik Laake4, Morten Hylander Møller3.   

Abstract

OBJECTIVE: To evaluate the effect of blinding on mortality effect estimates in randomized clinical trials (RCTs) in adult intensive care unit (ICU) patients. STUDY DESIGN AND
SETTING: A systematic review and meta-analysis of RCTs reporting mortality effect estimates of ICU interventions in adult ICU patients. We assessed differences in summarized risk ratios with 95% confidence intervals between blinded and unblinded RCTs. P < 0.10 was considered statistically significant (test of interaction).
RESULTS: We included 22 ICU interventions assessed in 269 RCTs enrolling a total of 42,007 adult ICU patients in the primary analyses. We observed statistically significant differences between blinded and unblinded RCTs for all-cause mortality at longest follow-up in one of 22 interventions (5%), for in-hospital mortality in one of 12 interventions (8%) but not for in-ICU mortality. Combining all interventions, unblinded trials reported larger summary effect estimates on all-cause mortality at longest follow-up compared to blinded trials (test of interaction, P = 0.09). However, the difference was not statistically significant following adjustment for other risk of bias domains.
CONCLUSIONS: We observed no firm evidence that lack of blinding affects estimates of mortality in RCTs of ICU interventions.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bias; Blinding; Effect estimates; Intensive care; Mortality

Mesh:

Year:  2018        PMID: 29705093     DOI: 10.1016/j.jclinepi.2018.04.016

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  5 in total

1.  Chasing the Ghost: Hyperinflammation Does Not Cause Sepsis.

Authors:  Leland Shapiro; Sias Scherger; Carlos Franco-Paredes; Amal A Gharamti; David Fraulino; Andrés F Henao-Martinez
Journal:  Front Pharmacol       Date:  2022-06-23       Impact factor: 5.988

2.  Evidence-based interventions to reduce mortality among preterm and low-birthweight neonates in low-income and middle-income countries: a systematic review and meta-analysis.

Authors:  Mirjam Y Kleinhout; Merel M Stevens; Kwabena Aqyapong Osman; Kwame Adu-Bonsaffoh; Floris Groenendaal; Nejimu Biza Zepro; Marcus J Rijken; Joyce L Browne
Journal:  BMJ Glob Health       Date:  2021-02

3.  Impact of early low-calorie low-protein versus standard-calorie standard-protein feeding on outcomes of ventilated adults with shock: design and conduct of a randomised, controlled, multicentre, open-label, parallel-group trial (NUTRIREA-3).

Authors:  Jean Reignier; Amélie Le Gouge; Jean-Baptiste Lascarrou; Djillali Annane; Laurent Argaud; Yannick Hourmant; Pierre Asfar; Julio Badie; Mai-Anh Nay; Nicolae-Vlad Botoc; Laurent Brisard; Hoang-Nam Bui; Delphine Chatellier; Louis Chauvelot; Alain Combes; Christophe Cracco; Michael Darmon; Vincent Das; Matthieu Debarre; Agathe Delbove; Jérôme Devaquet; Sebastian Voicu; Nadia Aissaoui-Balanant; Louis-Marie Dumont; Johanna Oziel; Olivier Gontier; Samuel Groyer; Bertrand Guidet; Samir Jaber; Fabien Lambiotte; Christophe Leroy; Philippe Letocart; Benjamin Madeux; Julien Maizel; Olivier Martinet; Frédéric Martino; Emmanuelle Mercier; Jean-Paul Mira; Saad Nseir; Walter Picard; Gael Piton; Gaetan Plantefeve; Jean-Pierre Quenot; Anne Renault; Laurent Guérin; Jack Richecoeur; Jean Philippe Rigaud; Francis Schneider; Daniel Silva; Michel Sirodot; Bertrand Souweine; Florian Reizine; Fabienne Tamion; Nicolas Terzi; Didier Thévenin; Guillaume Thiéry; Nathalie Thieulot-Rolin; Jean-François Timsit; François Tinturier; Patrice Tirot; Thierry Vanderlinden; Isabelle Vinatier; Christophe Vinsonneau; Diane Maugars; Bruno Giraudeau
Journal:  BMJ Open       Date:  2021-05-11       Impact factor: 2.692

4.  The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19?

Authors:  Kate C Tatham; Manu Shankar-Hari; Yaseen M Arabi
Journal:  Intensive Care Med       Date:  2021-10-07       Impact factor: 17.440

5.  Cerebral near-infrared spectroscopy monitoring versus treatment as usual for extremely preterm infants: a protocol for the SafeBoosC randomised clinical phase III trial.

Authors:  Mathias Lühr Hansen; Adelina Pellicer; Christian Gluud; Eugene Dempsey; Jonathan Mintzer; Simon Hyttel-Sørensen; Anne Marie Heuchan; Cornelia Hagmann; Ebru Ergenekon; Gabriel Dimitriou; Gerhard Pichler; Gunnar Naulaers; Guoqiang Cheng; Hercilia Guimarães; Jakub Tkaczyk; Karen B Kreutzer; Monica Fumagalli; Olivier Claris; Petra Lemmers; Siv Fredly; Tomasz Szczapa; Topun Austin; Janus Christian Jakobsen; Gorm Greisen
Journal:  Trials       Date:  2019-12-30       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.